| Announcement | Date |
|---|---|
Dear HCP Letter: Communication of new safety information for XELJANZ (tofacitinib) |
March 1, 2019 |
Pfizer Announces Modification To Ongoing Tofacitinib FDA Post-Marketing Requirement Study In Patients With Rheumatoid Arthritis |
February 20, 2019 |
Introducing Partner4BetterWe are pleased to introduce a new initiative by Pfizer Medical Information called Partner 4 Better. This program provides educational content to support evidence-based decision making and the responsible use of medicines. |
November 6, 2018 |
Exact Sciences and Pfizer Enter into a U.S. Agreement for Cologuard®On August 22, 2018, Exact Sciences Corp. and Pfizer Inc. announced an agreement to co-promote Cologuard, the FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer joins Exact Sciences' colleagues in reaching both physicians and health systems and also actively participates in extending and deepening the Cologuard development. For further medical information, please call Exact Sciences Provider Support Line 1-844-870-8870 |
October 8, 2018 |